Skip to main content

Advertisement

Articles

Page 1 of 96

  1. The immune microenvironment in ductal carcinoma in situ (DCIS) and its significance are not well established. This study was conducted to evaluate the immune microenvironment of DCIS including the composition ...

    Authors: Milim Kim, Yul Ri Chung, Hyun Jeong Kim, Ji Won Woo, Soomin Ahn and So Yeon Park

    Citation: Breast Cancer Research 2020 22:32

    Content type: Research article

    Published on:

  2. After publication of the original article [1], we were notified that the wrong version of Fig. 2b has been published

    Authors: Pankaj Chaudhary, Lee D. Gibbs, Sayantan Maji, Cheryl M. Lewis, Sumihiro Suzuki and Jamboor K. Vishwanatha

    Citation: Breast Cancer Research 2020 22:31

    Content type: Correction

    Published on:

    The original article was published in Breast Cancer Research 2020 22:11

  3. Breast cancer is rare in men, but management is focused on tumor characteristics commonly found in female breast cancer. The tumor microenvironment of male breast cancer is less well understood, and insight ma...

    Authors: Si-Qi Qiu, Johan van Rooijen, Hilde H. Nienhuis, Bert van der Vegt, Hetty Timmer-Bosscha, Elise van Leeuwen-Stok, Annemiek M. E. Walenkamp, Carolien H. M. van Deurzen, Geertruida H. de Bock, Elisabeth G. E. de Vries and Carolien P. Schröder

    Citation: Breast Cancer Research 2020 22:30

    Content type: Research article

    Published on:

  4. Breast cancer patients with early-stage disease are increasingly administered neoadjuvant chemotherapy (NAC) to downstage their tumors prior to surgery. In this setting, approximately 31% of patients fail to r...

    Authors: Anup Tank, Hannah M. Peterson, Vivian Pera, Syeda Tabassum, Anais Leproux, Thomas O’Sullivan, Eric Jones, Howard Cabral, Naomi Ko, Rita S. Mehta, Bruce J. Tromberg and Darren Roblyer

    Citation: Breast Cancer Research 2020 22:29

    Content type: Research article

    Published on:

  5. After the publication of the original article [1], we were notified the upper panel of the Fig. 1, where the patients’ codes are listed, was cropped by mistake so the patients 1–8 are repeated.

    Authors: Adi Zundelevich, Maya Dadiani, Smadar Kahana-Edwin, Amit Itay, Tal Sella, Moran Gadot, Karen Cesarkas, Sarit Farage-Barhom, Efrat Glick Saar, Eran Eyal, Nitzan Kol, Anya Pavlovski, Nora Balint-Lahat, Daniela Dick-Necula, Iris Barshack, Bella Kaufman…

    Citation: Breast Cancer Research 2020 22:28

    Content type: Correction

    Published on:

    The original article was published in Breast Cancer Research 2020 22:16

  6. Palbociclib improves outcomes for women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC). Dose reductions are recommended for the manageme...

    Authors: Johannes Ettl, Seock-Ah Im, Jungsil Ro, Norikazu Masuda, Marco Colleoni, Patrick Schnell, Eustratios Bananis, Dongrui R. Lu, Massimo Cristofanilli, Hope S. Rugo and Richard S. Finn

    Citation: Breast Cancer Research 2020 22:27

    Content type: Research article

    Published on:

  7. Breast cancer stem cells (BCSCs) are typically seed cells of breast tumor that initiate and maintain tumor growth. MiR-7, as a cancer inhibitor, decreases the BCSC subset and inhibits tumor progression through...

    Authors: Miao Li, Meng Pan, Chengzhong You, Fengshu Zhao, Di Wu, Mei Guo, Hui Xu, Fangfang Shi, Danfeng Zheng and Jun Dou

    Citation: Breast Cancer Research 2020 22:26

    Content type: Research article

    Published on:

  8. After publication of the original article [1], we were notified that columns in Table 2 were erroneously displayed.

    Authors: Nasim Mavaddat, Antonis C. Antoniou, Thea M. Mooij, Maartje J. Hooning, Bernadette A. Heemskerk-Gerritsen, Catherine Noguès, Marion Gauthier-Villars, Olivier Caron, Paul Gesta, Pascal Pujol, Alain Lortholary, Daniel Barrowdale, Debra Frost, D. Gareth Evans, Louise Izatt, Julian Adlard…

    Citation: Breast Cancer Research 2020 22:25

    Content type: Correction

    Published on:

    The original article was published in Breast Cancer Research 2020 22:8

  9. Experimental and epidemiological studies demonstrate a role for 27-hydroxycholesterol (27HC) in breast cancer development, though results are conflicting. Cholesterol 27-hydroxylase (CYP27A1) and oxysterol 7-a...

    Authors: Charlotte Le Cornet, Britta Walter, Disorn Sookthai, Theron S. Johnson, Tilman Kühn, Ester Herpel, Rudolf Kaaks and Renée T. Fortner

    Citation: Breast Cancer Research 2020 22:23

    Content type: Research article

    Published on:

  10. In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine t...

    Authors: Christos Vaklavas, Brian S. Roberts, Katherine E. Varley, Nancy U. Lin, Minetta C. Liu, Hope S. Rugo, Shannon Puhalla, Rita Nanda, Anna Maria Storniolo, Lisa A. Carey, Mansoor N. Saleh, Yufeng Li, Jennifer F. Delossantos, William E. Grizzle, Albert F. LoBuglio, Richard M. Myers…

    Citation: Breast Cancer Research 2020 22:22

    Content type: Research article

    Published on:

  11. Polygenic factors are estimated to account for an additional 18% of the familial relative risk of breast cancer, with those at the highest level of polygenic risk distribution having a least a twofold increase...

    Authors: Tatiane Yanes, Mary-Anne Young, Bettina Meiser and Paul A. James

    Citation: Breast Cancer Research 2020 22:21

    Content type: Review

    Published on:

  12. As a consequence of responding to colleagues who asked about the publication of the original article [1], the authors have determined that the data published in Table 4 of the paper are incorrect.

    Authors: Danielle H. Bodicoat, Minouk J. Schoemaker, Michael E. Jones, Emily McFadden, James Griffin, Alan Ashworth and Anthony J. Swerdlow

    Citation: Breast Cancer Research 2020 22:19

    Content type: Correction

    Published on:

    The original article was published in Breast Cancer Research 2014 16:R18

  13. The molecular mechanisms underlying the association between increased adiposity and aggressive breast cancer phenotypes remain unclear, but likely involve the adipokines, leptin (LEP) and adiponectin (ADIPOQ),...

    Authors: Adana A. M. Llanos, Yong Lin, Wenjin Chen, Song Yao, Jorden Norin, Marina A. Chekmareva, Coral Omene, Lei Cong, Angela R. Omilian, Thaer Khoury, Chi-Chen Hong, Shridar Ganesan, David J. Foran, Michael Higgins, Christine B. Ambrosone, Elisa V. Bandera…

    Citation: Breast Cancer Research 2020 22:18

    Content type: Research article

    Published on:

  14. Emerging mutations in the ESR1 gene that encodes for the estrogen receptor (ER) are associated with resistance to endocrine therapy. ESR1 mutations rarely exist in primary tumors (~ 1%) but are relatively common ...

    Authors: Adi Zundelevich, Maya Dadiani, Smadar Kahana-Edwin, Amit Itay, Tal Sella, Moran Gadot, Karen Cesarkas, Sarit Farage-Barhom, Efrat Glick Saar, Eran Eyal, Nitzan Kol, Anya Pavlovski, Nora Balint-Lahat, Daniela Dick-Necula, Iris Barshack, Bella Kaufman…

    Citation: Breast Cancer Research 2020 22:16

    Content type: Research article

    Published on:

    The Correction to this article has been published in Breast Cancer Research 2020 22:28

  15. After publication of the original article [1], we were notified that an author’s surname has been erroneously spelled. Elisabetta Maragoni’s family name should be replaced with Marangoni.

    Authors: Sunil Pancholi, Mariana Ferreira Leal, Ricardo Ribas, Nikiana Simigdala, Eugene Schuster, Sophie Chateau-Joubert, Lila Zabaglo, Margaret Hills, Andrew Dodson, Qiong Gao, Stephen R. Johnston, Mitch Dowsett, Sabina C. Cosulich, Elisabetta Marangoni and Lesley-Ann Martin

    Citation: Breast Cancer Research 2020 22:14

    Content type: Correction

    Published on:

    The original article was published in Breast Cancer Research 2019 21:135

  16. In patients with hormone receptor-positive breast cancer, differentiating between patients with a low and a high risk of recurrence is an ongoing challenge. In current practice, prognostic clinical parameters ...

    Authors: Tim C. de Ruijter, Frank van der Heide, Kim M. Smits, Maureen J. Aarts, Manon van Engeland and Vivianne C. G. Heijnen

    Citation: Breast Cancer Research 2020 22:13

    Content type: Research article

    Published on:

  17. Breast cancer intrinsic molecular subtype (IMS) as classified by the expression-based PAM50 assay is considered a strong prognostic feature, even when controlled for by standard clinicopathological features su...

    Authors: Mustafa I. Jaber, Bing Song, Clive Taylor, Charles J. Vaske, Stephen C. Benz, Shahrooz Rabizadeh, Patrick Soon-Shiong and Christopher W. Szeto

    Citation: Breast Cancer Research 2020 22:12

    Content type: Research article

    Published on:

  18. Limited information is available on biomarker(s) for triple-negative breast cancer (TNBC) that can address the higher incidence and aggressiveness of TNBC in African-American (AA) women. Our previous studies h...

    Authors: Pankaj Chaudhary, Lee D. Gibbs, Sayantan Maji, Cheryl M. Lewis, Sumihiro Suzuki and Jamboor K. Vishwanatha

    Citation: Breast Cancer Research 2020 22:11

    Content type: Research article

    Published on:

    The Correction to this article has been published in Breast Cancer Research 2020 22:31

  19. Adjuvant radiotherapy (RT) for breast cancer (BC) has been associated with an increased risk of ischemic heart disease (IHD). We examined the incidence of IHD in a large population-based cohort of women with BC.

    Authors: Anna-Karin Wennstig, Charlotta Wadsten, Hans Garmo, Irma Fredriksson, Carl Blomqvist, Lars Holmberg, Greger Nilsson and Malin Sund

    Citation: Breast Cancer Research 2020 22:10

    Content type: Research article

    Published on:

  20. After the publication of this work [1] the authors have reported that in Table 3 The letter “T” in columns 5 and 7 should not be there.

    Authors: Samuel A. Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, James M. Orcutt, Marina E. Cazzaniga, Fanny Piette, Silvia Antolín, Elena Aguirre, Javier Cortes, Antonio Llombart-Cussac, Serena Di Cosimo, Rim S. Kim, Huichen Feng, Corey Lipchik…

    Citation: Breast Cancer Research 2020 22:9

    Content type: Correction

    Published on:

    The original article was published in Breast Cancer Research 2019 21:133

  21. The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantiall...

    Authors: Nasim Mavaddat, Antonis C. Antoniou, Thea M. Mooij, Maartje J. Hooning, Bernadette A. Heemskerk-Gerritsen, Catherine Noguès, Marion Gauthier-Villars, Olivier Caron, Paul Gesta, Pascal Pujol, Alain Lortholary, Daniel Barrowdale, Debra Frost, D. Gareth Evans, Louise Izatt, Julian Adlard…

    Citation: Breast Cancer Research 2020 22:8

    Content type: Research article

    Published on:

    The Correction to this article has been published in Breast Cancer Research 2020 22:25

  22. The p66ShcA redox protein is the longest isoform of the Shc1 gene and is variably expressed in breast cancers. In response to a variety of stress stimuli, p66ShcA becomes phosphorylated on serine 36, which allows...

    Authors: Kyle Lewis, Alex Kiepas, Jesse Hudson, Julien Senecal, Jacqueline R. Ha, Elena Voorand, Matthew G. Annis, Valerie Sabourin, Ryuhjin Ahn, Rachel La Selva, Sébastien Tabariès, Brian E. Hsu, Matthew J. Siegel, Matthew Dankner, Eduardo Cepeda Canedo, Mathieu Lajoie…

    Citation: Breast Cancer Research 2020 22:7

    Content type: Research article

    Published on:

  23. Distinguishing ductal carcinoma in situ (DCIS) from invasive ductal carcinoma (IDC) regions in clinical biopsies constitutes a diagnostic challenge. Spatial transcriptomics (ST) is an in situ capturing method,...

    Authors: Niyaz Yoosuf, José Fernández Navarro, Fredrik Salmén, Patrik L. Ståhl and Carsten O. Daub

    Citation: Breast Cancer Research 2020 22:6

    Content type: Research article

    Published on:

  24. Several dietary factors have been reported to be associated with risk of breast cancer, but to date, unequivocal evidence only exists for alcohol consumption. We sought to systematically assess the association...

    Authors: Alicia K. Heath, David C. Muller, Piet A. van den Brandt, Nikos Papadimitriou, Elena Critselis, Marc Gunter, Paolo Vineis, Elisabete Weiderpass, Guy Fagherazzi, Heiner Boeing, Pietro Ferrari, Anja Olsen, Anne Tjønneland, Patrick Arveux, Marie-Christine Boutron-Ruault, Francesca Romana Mancini…

    Citation: Breast Cancer Research 2020 22:5

    Content type: Research article

    Published on:

  25. Cancer stem cells (CSCs) are purported to be responsible for tumor initiation, treatment resistance, disease recurrence, and metastasis. CXCR1, one of the receptors for CXCL8, was identified on breast cancer (...

    Authors: Lori J. Goldstein, Raymond P. Perez, Denise Yardley, Linda K. Han, James M. Reuben, Hui Gao, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Yi Liu, Roberto R. Rosato and Jenny C. Chang

    Citation: Breast Cancer Research 2020 22:4

    Content type: Research article

    Published on:

  26. Breast cancer metastasis is driven by a profound remodeling of the cytoskeleton that enables efficient cell migration and invasion. Anillin is a unique scaffolding protein regulating major cytoskeletal structu...

    Authors: Dongdong Wang, Nayden G. Naydenov, Mikhail G. Dozmorov, Jennifer E. Koblinski and Andrei I. Ivanov

    Citation: Breast Cancer Research 2020 22:3

    Content type: Research article

    Published on:

  27. Endocrine therapy reduces breast cancer mortality by 40%, but resistance remains a major clinical problem. In this study, we sought to investigate the impact of aromatase inhibitor (AI) therapy on gene express...

    Authors: Qiong Gao, Elena López-Knowles, Maggie Chon U. Cheang, James Morden, Ricardo Ribas, Kally Sidhu, David Evans, Vera Martins, Andrew Dodson, Anthony Skene, Chris Holcombe, Elizabeth Mallon, Abigail Evans, Judith M. Bliss, John Robertson, Ian Smith…

    Citation: Breast Cancer Research 2019 22:2

    Content type: Research article

    Published on:

  28. Epertinib (S-222611) is a potent reversible inhibitor of HER2, EGFR and HER4. This trial evaluated the safety, tolerability, pharmacokinetics and antitumour activity of daily oral epertinib combined with trast...

    Authors: Iain R. Macpherson, Pavlina Spiliopoulou, Saeed Rafii, Matilde Saggese, Richard D. Baird, Javier Garcia-Corbacho, Antoine Italiano, Jacques Bonneterre, Mario Campone, Nicola Cresti, John Posner, Yousuke Takeda, Akinori Arimura and James Spicer

    Citation: Breast Cancer Research 2019 22:1

    Content type: Research article

    Published on:

  29. Invasive lobular carcinomas (ILCs) account for 10–15% of all breast cancers. They are characterized by an elevated endocrine responsiveness and by a long lasting risk of relapse over time. Here we report for t...

    Authors: Fabio Conforti, Laura Pala, Eleonora Pagan, Giuseppe Viale, Vincenzo Bagnardi, Giulia Peruzzotti, Tommaso De Pas, Nadia Bianco, Rossella Graffeo, Elena Guerini Rocco, Andrea Vingiani, Richard D. Gelber, Alan S. Coates, Marco Colleoni and Aron Goldhirsch

    Citation: Breast Cancer Research 2019 21:153

    Content type: Research article

    Published on:

  30. PIK3CA mutations are frequent in human breast cancer. Pik3caH1047R mutant expression in mouse mammary gland promotes tumorigenesis. TP53 mutations co-occur with PIK3CA mutations in human breast cancers. We previo...

    Authors: Wenlin Yuan, Leonard D. Goldstein, Steffen Durinck, Ying-Jiun Chen, Thong T. Nguyen, Noelyn M. Kljavin, Ethan S. Sokol, Eric W. Stawiski, Benjamin Haley, James Ziai, Zora Modrusan and Somasekar Seshagiri

    Citation: Breast Cancer Research 2019 21:152

    Content type: Research article

    Published on:

  31. Breast cancer (BC) immune infiltrates play a critical role in tumor progression and response to treatment. Besides stromal tumor infiltrating lymphocytes (sTILs) which have recently reached level 1B evidence a...

    Authors: Iris Nederlof, Davide De Bortoli, Yacine Bareche, Bastien Nguyen, Michiel de Maaker, Gerrit K. J. Hooijer, Laurence Buisseret, Marleen Kok, Marcel Smid, Gert G. G. M. Van den Eynden, Arie B. Brinkman, Jan Hudecek, Jan Koster, Christos Sotiriou, Denis Larsimont, John W. M. Martens…

    Citation: Breast Cancer Research 2019 21:151

    Content type: Research article

    Published on:

  32. CDK4/6 inhibitors in combination with endocrine therapy (AE/AI/SERDs) are approved for the treatment of ER+ advanced breast cancer (BCa). However, not all patients benefit from CDK4/6 inhibitors therapy. We pr...

    Authors: Suryavathi Viswanadhapalli, Shihong Ma, Gangadhara Reddy Sareddy, Tae-Kyung Lee, Mengxing Li, Collin Gilbreath, Xihui Liu, Yiliao Luo, Uday P. Pratap, Mei Zhou, Eliot B. Blatt, Kara Kassees, Carlos Arteaga, Prasanna Alluri, Manjeet Rao, Susan T. Weintraub…

    Citation: Breast Cancer Research 2019 21:150

    Content type: Research article

    Published on:

  33. Breast cancer (BC) is the most common cancer in women, and despite the introduction of new screening programmes, therapies and monitoring technologies, there is still a need to develop more useful tests for mo...

    Authors: Daniel Fernandez-Garcia, Allison Hills, Karen Page, Robert K. Hastings, Bradley Toghill, Kate S. Goddard, Charlotte Ion, Olivia Ogle, Anna Rita Boydell, Kelly Gleason, Mark Rutherford, Adrian Lim, David S. Guttery, R. Charles Coombes and Jacqueline A. Shaw

    Citation: Breast Cancer Research 2019 21:149

    Content type: Research article

    Published on:

  34. A role for neural precursor cell-expressed developmentally downregulated gene 4 (NEDD4) in tumorigenesis has been suggested. However, information is lacking on its role in breast tumor biology. The purpose of ...

    Authors: Lingfeng Wan, Tao Liu, Zhipeng Hong, You Pan, Steven T. Sizemore, Junran Zhang and Zhefu Ma

    Citation: Breast Cancer Research 2019 21:148

    Content type: Research article

    Published on:

  35. Heterogeneity of immune gene expression patterns of luminal breast cancer (BC), which is clinically heterogeneous and overall considered as low immunogenic, has not been well studied especially in non-European...

    Authors: Bin Zhu, Lap Ah Tse, Difei Wang, Hela Koka, Tongwu Zhang, Mustapha Abubakar, Priscilla Lee, Feng Wang, Cherry Wu, Koon Ho Tsang, Wing-cheong Chan, Sze Hong Law, Mengjie Li, Wentao Li, Suyang Wu, Zhiguang Liu…

    Citation: Breast Cancer Research 2019 21:147

    Content type: Research article

    Published on:

  36. Addition of CDK4/6 inhibitors (CDK4/6i) to endocrine therapy significantly increased progression-free survival, leading to their approval and incorporation into the metastatic breast cancer treatment paradigm....

    Authors: Hitisha K. Patel, Nianjun Tao, Kyung-Min Lee, Mariela Huerta, Heike Arlt, Tara Mullarkey, Steven Troy, Carlos L. Arteaga and Teeru Bihani

    Citation: Breast Cancer Research 2019 21:146

    Content type: Research article

    Published on:

  37. The formation of neutrophil extracellular traps (NETs), known as NETosis, was first observed as a novel immune response to bacterial infection, but has since been found to occur abnormally in a variety of othe...

    Authors: Hunter T. Snoderly, Brian A. Boone and Margaret F. Bennewitz

    Citation: Breast Cancer Research 2019 21:145

    Content type: Review

    Published on:

  38. Breast cancer survivors are at risk for contralateral breast cancer (CBC), with the consequent burden of further treatment and potentially less favorable prognosis. We aimed to develop and validate a CBC risk ...

    Authors: Daniele Giardiello, Ewout W. Steyerberg, Michael Hauptmann, Muriel A. Adank, Delal Akdeniz, Carl Blomqvist, Stig E. Bojesen, Manjeet K. Bolla, Mariël Brinkhuis, Jenny Chang-Claude, Kamila Czene, Peter Devilee, Alison M. Dunning, Douglas F. Easton, Diana M. Eccles, Peter A. Fasching…

    Citation: Breast Cancer Research 2019 21:144

    Content type: Research article

    Published on:

  39. Metastatic triple-negative breast cancer (mTNBC), an aggressive histological subtype, has poor prognosis. Chemotherapy remains standard of care for mTNBC, although no agent has been specifically approved for t...

    Authors: Claire H. Li, Vassiliki Karantza, Gursel Aktan and Mallika Lala

    Citation: Breast Cancer Research 2019 21:143

    Content type: Research article

    Published on:

  40. Clinical application of cancer immunotherapy requires a better understanding of tumor immunogenicity and the tumor microenvironment. HLA class I molecules present antigens to CD8+ cytotoxic cells. Their loss or d...

    Authors: Bruno Valentin Sinn, Karsten E. Weber, Wolfgang Daniel Schmitt, Peter A. Fasching, William Fraser Symmans, Jens-Uwe Blohmer, Thomas Karn, Eliane Tabea Taube, Frederick Klauschen, Frederik Marmé, Christian Schem, Elmar Stickeler, Beyhan Ataseven, Jens Huober, Gunter von Minckwitz, Barbara Seliger…

    Citation: Breast Cancer Research 2019 21:142

    Content type: Research article

    Published on:

  41. Organoid cultures are increasingly used to model human cancers experimentally with a view to tailoring personalized medicine and predicting drug responses. Breast cancer is no exception, but in particular, pri...

    Authors: Nadine Goldhammer, Jiyoung Kim, Vera Timmermans-Wielenga and Ole William Petersen

    Citation: Breast Cancer Research 2019 21:141

    Content type: Short report

    Published on:

  42. Breast cancer is the most common cancer to affect women and one of the leading causes of cancer-related deaths. Proper regulation of cell cycle checkpoints plays a critical role in preventing the accumulation ...

    Authors: Bre-Anne Fifield, Ingrid Qemo, Evie Kirou, Robert D. Cardiff and Lisa Ann Porter

    Citation: Breast Cancer Research 2019 21:140

    Content type: Research article

    Published on:

  43. An increasing number of women are evaluated for potential breast cancer and may experience mental distress during evaluation. We aim to assess the risks of psychiatric disorders and cardiovascular diseases dur...

    Authors: Qing Shen, Anna Jöud, Maria E. C. Schelin, Arvid Sjölander, Yang Cao, Pär Sparén, Katja Fall, Kamila Czene, Unnur Valdimarsdóttir and Fang Fang

    Citation: Breast Cancer Research 2019 21:139

    Content type: Research article

    Published on:

  44. The tumor suppressor actions of hexamethylene bis-acetamide (HMBA)-inducible protein 1 (HEXIM1) in the breast, prostate, melanomas, and AML have been reported by our group and others. Increased HEXIM1 expressi...

    Authors: Monica M. Montano, I-Ju Yeh, Yinghua Chen, Chris Hernandez, Janna G. Kiselar, Maria de la Fuente, Adriane M. Lawes, Marvin T. Nieman, Philip D. Kiser, James Jacobberger, Agata A. Exner and Matthew C. Lawes

    Citation: Breast Cancer Research 2019 21:138

    Content type: Research article

    Published on:

  45. Liquid biopsies, including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), can be used to understand disease prognosis, tumor heterogeneity, and dynamic response to treatment in metastatic br...

    Authors: Andrew A. Davis, Qiang Zhang, Lorenzo Gerratana, Ami N. Shah, Youbin Zhan, Wenan Qiang, Brian S. Finkelman, Lisa Flaum, Amir Behdad, William J. Gradishar, Leonidas C. Platanias and Massimo Cristofanilli

    Citation: Breast Cancer Research 2019 21:137

    Content type: Research article

    Published on:

  46. CGRRF1 is a growth suppressor and consists of a transmembrane domain and a RING-finger domain. It functions as a RING domain E3 ubiquitin ligase involved in endoplasmic reticulum-associated degradation. The ex...

    Authors: Yu-Ju Lee, Shiuh-Rong Ho, Joshua D. Graves, Yang Xiao, Shixia Huang and Weei-Chin Lin

    Citation: Breast Cancer Research 2019 21:134

    Content type: Research article

    Published on:

Annual Journal Metrics

Advertisement